• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24117 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Agency for Care Effectiveness (ACE) Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021     Agency for Care Effectiveness (ACE) Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2024     Agency for Care Effectiveness (ACE) Tolvaptan for treating autosomal dominant polycystic kidney disease
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2024     Agency for Care Effectiveness (ACE) Ruxolitinib for treating graft-versus-host disease
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2024     Agency for Care Effectiveness (ACE) Nusinersen and risdiplam for treating spinal muscular atrophy
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2024     Agency for Care Effectiveness (ACE) Enzyme replacement therapies for Fabry disease
2021     Agency for Care Effectiveness (ACE) Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2024     Agency for Care Effectiveness (ACE) Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine
2017     Agency for Care Effectiveness (ACE) Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
2024     Agency for Care Effectiveness (ACE) Burosumab for treating X-linked hypophosphataemia
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
2017     Agency for Care Effectiveness (ACE) Gliclazide for the treatment of type 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2017     Agency for Care Effectiveness (ACE) Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
2024     Agency for Care Effectiveness (ACE) Selexipag for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2024     Agency for Care Effectiveness (ACE) Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
2017     Agency for Care Effectiveness (ACE) Somatropin for the treatment of growth failure in children
2024     Agency for Care Effectiveness (ACE) Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
2017     Agency for Care Effectiveness (ACE) Gemcitabine for the treatment of cancer
2025     Agency for Care Effectiveness (ACE) Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2017     Agency for Care Effectiveness (ACE) Sumatriptan for the treatment of acute migraine attacks
2025     Agency for Care Effectiveness (ACE) Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2017     Agency for Care Effectiveness (ACE) Temozolomide for the treatment of malignant glioma
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2017     Agency for Care Effectiveness (ACE) Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Guardant360 CDx for patients with locally advanced or metastatic non-small cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2022     Agency for Care Effectiveness (ACE) The Signatera test for patients previously diagnosed with cancer
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2018     Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2025     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2025     Agency for Care Effectiveness (ACE) Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2024     Agency for Care Effectiveness (ACE) Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer
2018     Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2025     Agency for Care Effectiveness (ACE) Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2020     Agency for Care Effectiveness (ACE) Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2022     Agency for Care Effectiveness (ACE) Nivolumab for treating gastroesophageal cancers
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma
2018     Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2022     Agency for Care Effectiveness (ACE) Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2022     Agency for Care Effectiveness (ACE) SGLT2 inhibitors for treating heart failure with reduced ejection fraction and chronic kidney disease
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2022     Agency for Care Effectiveness (ACE) Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer
2018     Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2019     Agency for Care Effectiveness (ACE) Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019     Agency for Care Effectiveness (ACE) Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019     Agency for Care Effectiveness (ACE) Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2020     Agency for Care Effectiveness (ACE) Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2019     Agency for Care Effectiveness (ACE) Febuxostat for treating chronic hyperuricaemia in adults with gout
2020     Agency for Care Effectiveness (ACE) Ursodeoxycholic acid for treating primary biliary cirrhosis
2019     Agency for Care Effectiveness (ACE) Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019     Agency for Care Effectiveness (ACE) Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019     Agency for Care Effectiveness (ACE) Oral COX-2 inhibitors for treating pain
2019     Agency for Care Effectiveness (ACE) Ferric carboxymaltose for treating iron deficiency anaemia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating cervical dystonia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019     Agency for Care Effectiveness (ACE) Endothelin receptor antagonists for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020     Agency for Care Effectiveness (ACE) Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020     Agency for Care Effectiveness (ACE) Epoprostenol for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Vonoprazan for treating helicobacter pylori infection
2020     Agency for Care Effectiveness (ACE) Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2020     Agency for Care Effectiveness (ACE) Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020     Agency for Care Effectiveness (ACE) Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020     Agency for Care Effectiveness (ACE) Mycophenolate mofetil for immunosuppression
2020     Agency for Care Effectiveness (ACE) Adalimumab for treating inflammatory conditions
2020     Agency for Care Effectiveness (ACE) Abiraterone for treating metastatic prostate cancer
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2021     Agency for Care Effectiveness (ACE) Tenofovir alafenamide for treating chronic hepatitis B infection
2021     Agency for Care Effectiveness (ACE) Metformin extended release for treating type 2 diabetes mellitus
2021     Agency for Care Effectiveness (ACE) Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active psoriatic arthritis
2021     Agency for Care Effectiveness (ACE) Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active ankylosing spondylitis